Related references
Note: Only part of the references are listed.Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Nina G. Steele et al.
CLINICAL CANCER RESEARCH (2021)
A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
Alex Cazes et al.
CLINICAL CANCER RESEARCH (2021)
mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy
Koushik K. Das et al.
HUMAN PATHOLOGY (2021)
Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems
Rami Alzhrani et al.
DRUG DISCOVERY TODAY (2020)
Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer
Inna M. Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy
Ying Xie et al.
ACS NANO (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
Shipra Das et al.
CANCER RESEARCH (2020)
Cancer stem cells as therapeutic targets of pancreatic cancer
Ebrahim Razi et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2020)
Sonic Hedgehog Protein is Frequently Up-Regulated in Pancreatic Cancer Compared to Colorectal Cancer
Madiha Niyaz et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
Srinivasa P. Pothula et al.
PANCREATOLOGY (2020)
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
Daniel R. Principe et al.
CANCER RESEARCH (2020)
The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities
Won Jin Ho et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
Evangelos Koustas et al.
BIOMOLECULES (2020)
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Aaron J. Grossberg et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Implications of HIF-1 alpha in the tumorigenesis and progression of pancreatic cancer
Xiao Jin et al.
CANCER CELL INTERNATIONAL (2020)
Hypoxia and pancreatic ductal adenocarcinoma
Akio Yamasaki et al.
CANCER LETTERS (2020)
Immunotherapy for pancreatic cancer: A 2020 update
Dimitrios Schizas et al.
CANCER TREATMENT REVIEWS (2020)
Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression
Matthew Hadden et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Small molecule inhibitors in pancreatic cancer
Jufeng Sun et al.
RSC MEDICINAL CHEMISTRY (2020)
Updates in pancreatic cancer: Modest gains and hopeful targets
Amber Draper
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Inhibition of pancreatic cancer stem cell characteristics by α-Mangostin: Molecular mechanisms involving Sonic hedgehog and Nanog
Yiming Ma et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Gemcitabine, docetaxel, and capecitabine (GTX) as a first-line regimen in metastatic pancreatic adenocarcinomas (mPAC): A single institution experience.
Vikas Singh et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer-Associated Fibroblasts' Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma
Mohammad Awaji et al.
CANCERS (2019)
Deciphering role of FGFR signalling pathway in pancreatic cancer
Xiaodiao Kang et al.
CELL PROLIFERATION (2019)
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia
Paul C. McDonald et al.
GASTROENTEROLOGY (2019)
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2019)
Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis
Madelaine G. van Mackelenbergh et al.
CANCERS (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune Defects in the Tumor Microenvironment
Sireesha Upadhrasta et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
R. Govindan et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma
Giulia Brachi et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2019)
The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer
Huocong Huang et al.
CANCER RESEARCH (2019)
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
James R. W. Conway et al.
GUT (2019)
Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art
Sally A. El-Zahaby et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Feasibility of Acupuncture to Induce Sleep for Brainstem Auditory Evoked Response Testing
Nicole Holmer et al.
AMERICAN JOURNAL OF AUDIOLOGY (2019)
Gemcitabine primes the pancreatic tumor microenvironment for second-line immunotherapy
Daniel R. Principe et al.
CANCER RESEARCH (2019)
Transcytosis - An effective targeting strategy that is complementary to EPR effect for pancreatic cancer nano drug delivery
Xiangsheng Liu et al.
THERANOSTICS (2019)
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome
Ahmed Salem et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome
Ahmed Salem et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment
Xiao Zhao et al.
BIOMATERIALS (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
The biology and role of CD44 in cancer progression: therapeutic implications
Chen Chen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer
Ying Zhang et al.
MOLECULAR CANCER (2018)
CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer
Zhaoxian Wang et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Marc Hilmi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer
Hadas Gibori et al.
NATURE COMMUNICATIONS (2018)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer
James R. W. Conway et al.
CELL REPORTS (2018)
Role of Gene Therapy in Pancreatic Cancer-A Review
Mizuho Sato-Dahlman et al.
CANCERS (2018)
Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer
Tom Curran
OPEN BIOLOGY (2018)
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Derya Kabacaoglu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
Shravanti Macherla et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling
Andreia V. Pinho et al.
NATURE COMMUNICATIONS (2018)
Robo signalling controls pancreatic progenitor identity by regulating Tead transcription factors
Sophie Escot et al.
NATURE COMMUNICATIONS (2018)
Retrospective comparison of modified FOLFIRINOX with full-dose FOLFIRINOX for advanced pancreatic cancer: A Japanese cancer center experience.
Akihiro Ohba et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Kate Young et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models
Egor Bobrov et al.
ONCOTARGET (2017)
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Aleksandra Adamska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac
Thangirala Sudha et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development
Talia Golan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Vinod P. Balachandran et al.
NATURE (2017)
T-Cell Transfer Therapy Targeting Mutant KRAS
Asaf Maoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model
Carla Hajj et al.
TRANSLATIONAL ONCOLOGY (2017)
Germline mutations in pancreatic cancer and potential new therapeutic options
Rille Pihlak et al.
ONCOTARGET (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Sunjida Ahmed et al.
JOURNAL OF CLINICAL MEDICINE (2017)
1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA
N.H. Segal et al.
ANNALS OF ONCOLOGY (2017)
Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Safieh Ebrahimi et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells
Astrid Belalcazar et al.
CANCER (2017)
Endocytosis of cerium oxide nanoparticles and modulation of reactive oxygen species in human ovarian and colon cancer cells
James A. Vassie et al.
ACTA BIOMATERIALIA (2017)
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Janaiah Kota et al.
CANCER LETTERS (2017)
Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis
Begum Erdogan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials
Alessandro Ottaiano et al.
ACTA ONCOLOGICA (2017)
Nanotechnology for delivery of gemcitabine to treat pancreatic cancer
Gebremariam Birhanu et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy
Ibrahim H. Sahin et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer
Bo Zhang et al.
BIOMATERIALS (2016)
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
Simon Pernot et al.
BRITISH JOURNAL OF CANCER (2016)
Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight
Norihiro Sato et al.
CANCER SCIENCE (2016)
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy
Shujie Zhao et al.
CLINICAL CANCER RESEARCH (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
Role of immune cells in pancreatic cancer from bench to clinical application An updated review
Jae Hyuck Chang et al.
MEDICINE (2016)
Cancer stem cell metabolism: a potential target for cancer therapy
Abhijeet Deshmukh et al.
MOLECULAR CANCER (2016)
Smart targeted therapy by self-assembled supramolecular nanosystems
Kazunori Kataoka
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Pavan P. Adiseshaiah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
Andrew H. Ko et al.
PANCREAS (2016)
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Daniel Delitto et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Management of pancreatic cancer in the elderly
Oliver Higuera et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Kishore Polireddy et al.
JOURNAL OF CANCER (2016)
Activation of WNT/β- Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61
Makoto Sano et al.
NEOPLASIA (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Daniel Zeitouni et al.
CANCERS (2016)
Phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer
Makoto Ueno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer
Xiao Zhao et al.
BIOMATERIALS (2015)
Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
D. Masso-Valles et al.
CANCER RESEARCH (2015)
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
Xinzhe Yu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells
Ling Wang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
First-in-man Phase 1 Clinical Trial of Gene Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical Findings
Louis Buscail et al.
MOLECULAR THERAPY (2015)
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Frederick D. Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Immunological off-target effects of standard treatments in gastrointestinal cancers
A. G. Duffy et al.
ANNALS OF ONCOLOGY (2014)
Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways
Fabienne Guillaumond et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Single-cell technologies for monitoring immune systems
Pratip K. Chattopadhyay et al.
NATURE IMMUNOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Evaluation of the Steal Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer
Kate M. Bailey et al.
PLOS ONE (2014)
KRAS: feeding pancreatic cancer proliferation
Kirsten L. Bryant et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy
Amedeo Amedei et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity
Elisa Dalla Pozza et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2013)
Inflammatory networks and immune surveillance of pancreatic carcinoma
Robert H. Vonderheide et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer
Manikanta Swamy Murahari et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Loss of the Transcription Factor GLI1 Identifies a Signaling Network in the Tumor Microenvironment Mediating KRAS Oncogene-induced Transformation
Lisa D. Mills et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
Takeshi Ogura et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer
Kolaparthi Venkatasubbarao et al.
MOLECULAR CANCER (2013)
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production
Melissa S. Wason et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
Hemchandra Mahaseth et al.
PANCREAS (2013)
Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice
Atsushi Masamune et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Immune infiltrates as predictive markers of survival in pancreatic cancer patients
Maria Pia Protti et al.
FRONTIERS IN PHYSIOLOGY (2013)
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
J. Iqbal et al.
BRITISH JOURNAL OF CANCER (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
The Pancreas Cancer Microenvironment
Christine Feig et al.
CLINICAL CANCER RESEARCH (2012)
Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
Mitsuro Kanda et al.
GASTROENTEROLOGY (2012)
StellaTUM: current consensus and discussion on pancreatic stellate cell research
Mert Erkan et al.
GUT (2012)
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles
Frederico Pittella et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
Natalie Cook et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
Mert Erkan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
Eric Lutz et al.
ANNALS OF SURGERY (2011)
Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer
Qing Chang et al.
CANCER RESEARCH (2011)
c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
Chenwei Li et al.
GASTROENTEROLOGY (2011)
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer
Soukaina Rejiba et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2011)
TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression
M. Seux et al.
ONCOGENE (2011)
c-MET as a potential therapeutic target and biomarker in cancer
J. Rafael Sierra et al.
Therapeutic Advances in Medical Oncology (2011)
Cyclopamine and Hedgehog Signaling: Chemistry, Biology, Medical Perspectives
Philipp Heretsch et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice
Chiyo Doi et al.
BMC CANCER (2010)
Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
Xin Lu et al.
CLINICAL CANCER RESEARCH (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh et al.
NATURE BIOTECHNOLOGY (2010)
Targeted Delivery Systems for Oligonucleotide Therapeutics
Bo Yu et al.
AAPS JOURNAL (2009)
Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro
Jin-ming Li et al.
ACTA PHARMACOLOGICA SINICA (2009)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Selective Killing of Hypoxia-Inducible Factor-1-Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer
Shinae Kizaka-Kondoh et al.
CLINICAL CANCER RESEARCH (2009)
HIF at a glance
M. Christiane Brahimi-Horn et al.
JOURNAL OF CELL SCIENCE (2009)
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Hua Tian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Cancer-Stellate Cell Interactions Perpetuate the Hypoxia-Fibrosis Cycle in Pancreatic Ductal Adenocarcinoma
Mert M. Erkan et al.
NEOPLASIA (2009)
Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma
Tine S. Mantoni et al.
CANCER BIOLOGY & THERAPY (2008)
Cancer-associated stroma fibroblasts promote pancreatic tumor progression
Rosa F. Hwang et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
The use of GEM models for experimental cancer therapeutics
Aarthi Gopinathan et al.
DISEASE MODELS & MECHANISMS (2008)
A paracrine requirement for hedgehog signalling in cancer
Robert L. Yauch et al.
NATURE (2008)
Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue
Patrick Couvreur et al.
SMALL (2008)
Development and characterization of gemcitabine-resistant pancreatic tumor cells
Ami N. Shah et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
Patrick C. Hermann et al.
CELL STEM CELL (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of pancreatic cancer stem cells
Chenwei Li et al.
CANCER RESEARCH (2007)
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Catherine A. O'Brien et al.
NATURE (2007)
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Daruka Mahadevan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Drug penetration in solid tumours
Andrew I. Minchinton et al.
NATURE REVIEWS CANCER (2006)
Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-β1
Adam J. Ottaviano et al.
CANCER RESEARCH (2006)
Hypoxia signalling in cancer and approaches to enforce tumour regression
Jacques Pouyssegur et al.
NATURE (2006)
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
F Di Costanzo et al.
BRITISH JOURNAL OF CANCER (2005)
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
M Reni et al.
LANCET ONCOLOGY (2005)
Cancer therapy: can the challenge be MET?
S Corso et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma
T Armstrong et al.
CLINICAL CANCER RESEARCH (2004)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray
A Maitra et al.
MODERN PATHOLOGY (2003)
Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis
Y Miyamoto et al.
CANCER CELL (2003)
Adjuvant therapy in pancreatic cancer:: historical and current perspectives
JP Neoptolemos et al.
ANNALS OF ONCOLOGY (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells
R Jaster et al.
GUT (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells
E Schneider et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2001)
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
EM Jaffee et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Pancreatic tumors show high levels of hypoxia
AC Koong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
